ArticleWorld journal of gastrointestinal endoscopy2026
Lactated Ringer's solution in combination with indomethacin for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized trial.
Article in World journal of gastrointestinal endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProspective data have shown the benefit of rectal indomethacin (IND) in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Recent pilot studies demonstrated a lower incidence of PEP after an 8-hour lactated Ringer's solution (LR) infusion.
aimTo assess the efficacy of IND, with or without a bolus of LR, in patients at a high risk for PEP.
methodsIn this randomized, double-blinded controlled trial, we assigned patients to LR, IND, or LR + IND. Each liter of fluid infusion was completed within 30 minutes. Patients were determined to be high-risk based on established criteria and excluded if they had pancreatitis, contraindications to IND, or signs of volume overload. Our primary outcome was PEP, defined by standardized criterion. Our secondary outcomes were severe acute pancreatitis, localized adverse events, death, length of stay, and readmission.
resultsThe study sample included 210 patients (70 per group) who accomplished follow-up at 24 hours and 30 days post-endoscopic retrograde cholangiopancreatography. All patients presented at least one high-risk factor for PEP, with 59% having more than one. PEP was observed in 23 patients (10,9%): Five patients (7%) in the LR + IND group
conclusionIn high-risk patients for PEP, the combination of LR + IND decreased the incidence of PEP and readmission rates compared to LR or IND administered alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.